Roche divarasib head-to-head in KRAS-mutant lung cancer: 338 patients, response rate 58.4%

Roche reported phase III head-to-head results for divarasib on October 25. The trial randomized 338 previously treated KRAS G12C lung cancer patients; median overall survival was 17.7 months versus 12.0 months, with a 44% reduction in risk of death. The source describes it as the first phase III head-to-head study of a next-generation KRAS G12C inhibitor against an approved first-generation inhibitor, and the headline gives a response rate of 58.4%.